Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 1997

View Archived Issues

Celtrix Pharmaceuticals reports third-quarter results

Cypress Bioscience announces 1996 quarterly and year-end results

Cytogen announces 1996 fiscal results

Amylin Pharmaceuticals reports 1996 financial results

Avigen reports second-quarter 1997 results

Biovail Corp. reports record 1996 fourth-quarter and year-end financial results

La Jolla Pharmaceutical reports 1996 fourth-quarter and year-end financial results

Cell Genesys licenses gene activation technology

Senju prepares beta-blocker

TK inhibitors from Novartis

Thrombin inhibitors disclosed by Astra

Pharmacia & Upjohn claims antimigraine agents

Incyte describes novel human EDG-2 receptor homologue

MAb for metastasis or ischemia reported by BU

Selective, nonpeptide inhibitor of Ras farnesylation discovered by Schering-Plough

Abbott describes AK inhibitor with anticonvulsant/neuroprotective effects

Zeneca presents potent and selective ETA receptor antagonist

Glaxo Wellcome evaluates melatonin agonist

Potential agent for hypertension and CHF from Roche Bioscience

Dual NEP/ECE inhibitor for heart failure

MorphoSys/P&U drug and target discovery collaboration

MGH to evaluate Cheung breast cancer treatment system in animals

IVAX receives approval for generic NSAID

Watson's mexiletine approved

Start-up company funded by Oxford Molecular

Antisense-based drug highly effective for eradicating RSV

Neuroimmunophilin ligand shows promise for Parkinson's disease

RPR forms worldwide research collaboration to study Taxotere-based combinations

Nonsurgical treatment for vitreous hemorrhage enters clinic in the U.S.

IntelliGene licenses ribozymes for diagnostics

Allelix reports progress in osteoporosis trial

Bayer initiates international diabetes prevention project

Abelcet receives additional European approval

Ebrotidine introduced in Spain

Cypros receives SBIR grant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...